u,' Preliminary in vitro experiments were performed to determine the serum concentration of serotonin in the monkey, and the ability of cyproheptadine to block serotonin and serum-induced contractions in monkey cerebral arteries. Thirty-four cynomolgus monkeys were subsequently used to study changes in regional cerebral blood flow (CBF) obtained by the intracarotid x88Xe technique, and in the angiographic cerebral arterial caliber resulting from subarachnoid injection of artificial cerebrospinal fluid (CSF), blood, and serotonin. Five animals in each injection group were given 1.0 mg/kg intravenous cyproheptadine (a serotonin-blocking agent) during the post-injection period.
B
ECAUSE of widespread belief that cerebral vasospasm is a major factor contributing to the development of cerebral ischemia in patients with subarachnoid hemorrhage (SAH), intensive research has been carried out in an attempt to identify the factor(s) in blood that are capable of producing prolonged constriction of the cerebral arteries. At present, the bulk of accumulated evidence points toward a chemical vasoconstrictive agent that is liberated from the blood present in the subarachnoid space. Many such agents have been identified in blood (for instance, serotonin, prostaglandins, norepinephrine), and each has its proponents as the agent causing cerebral vasospasm in man. However, recent evidence, particularly from in vitro studies, appears to favor serotonin as the major spasmogenic agent. 1-4' 18 ' 18 The present study was designed to assess the spasmogenic ability of serotonin in a primate model, to determine the relationship between serotonininduced vasospasm and cerebral blood flow (CBF), and to compare the results to those obtained under the same conditions with artificial cerebrospinal fluid (CSF) and blood.
Materials and Methods

In Vitro Experiments
In vitro experiments were carried out to obtain an estimate of the normal concentration of serum serotonin in monkey serum. The results of these experiments determined the concentration of the serotonin solution to be injected into the subarachnoid space in the experiments in vivo. A second set of experiments in vitro was conducted to verify the ability of cyproheptadine to block contractions in monkey cerebral arteries induced by serotonin and serum.
Tissues known to be reactive to serotonin (Table 1) were placed into cooled, oxygenated, modified Krebs-Henseliet solution after dissection. Spiral strips of these tissues were then cut and mounted in jacketed 5-or 10-ml organ baths maintained at 37 ~ C, and aerated with a 5% CO2/95% gas mixture (pH --7.4). After a 2-hour recovery period, the response of the tissue to various agents (serotonin, cyproheptadine, monkey serum) was tested. Isometric tissue responses were measured using a force displacement transducer, connected to a Grass 4-channel polygraph (model 5-D) or a Beckman dynograph.* The modified KrebsHenseliet solution bathing the tissues in the organ had the following composition: Na § 117.5 mM; Ca ++, 2.5 mM; CI-, 127.9 mM; POi s, 1.2 mM; K +, 5.4 mM; Mg §247 0.6 mM; SOt, 0.6 mM; glucose, 11.1 mM.
Monkey serum serotonin concentrations were estimated by comparing serum-induced contractions to contractions obtained using known concentrations of serotonin. A minimum of two concentrations of serotonin and two concentrations of serum was used for each serum serotonin determination (four-point assay).
In other experiments in vitro, the response of the tissue (monkey cerebral arteries) to cumulative concentrations of serotonin or specific concentrations (5 X 10 -6 M) of serotonin and serum were determined in the presence and absence of the serotonin antagonist cyproheptadine at a concentration of 5 X 10 -6 M.
In Vivo Experiments
Thirty-four female cynomolgus (Macaca irus) monkeys weighing 2.3 to 4.2 kg were used for the study. Anesthesia for the surgical preparation was achieved with intravenous sodium pentothal (25 to 30 mg/kg). Light general anesthesia was subsequently maintained with a mixture of nitrous oxide and oxygen from a reservoir in a ratio of 2: 1. The animals were ventilated with a Harvard variable-phase respiratort and paralyzed with intravenous gallamine for the duration of the experiment. Body temperature was continuously monitored by an esophageal thermometer,~ and maintained between 36 ~ and 38 ~ C by a small heating pad positioned below the animals. 2.5 X 10 -6 2.2 X 10 -6 R-2 middle cerebral artery (dog) 2.0 X 10 -6 R-3 umbilical artery 3.5 X 10 -6 R-3 umbilical artery 6.2 X 10 -G 5.0 X 10 -6 R-3 umbilical artery 5.3 X 10 -6 R-4 basilar artery (dog)
1.2 X 10 -~ R-4 umbilical artery 2.3 X 10 -6 7.6 X 10 -6 R-4 umbilical artery 8.4 X 10 -6 R-5 umbilical artery 1.1 X 10-6 mean 8.0 • 10 -6 C-1 umbilical artery 6.9 X 10-6 C-2 umbilical artery 6.3 X 10 -6 C-3 umbilical artery 1.1 X 10 -5 C-4 umbilical artery 3.4 X 10 -6 C-5 umbilical artery 1.7 X 10 -5 C-6 stomach fundus (rat) 2.8 X 10 -6 C-6 stomach fundus 3.6 • 10 -6 C-7 stomach fundus 3.8 X 10 -8 C-7 stomach fundus 3.0 X 10 -6 3.4 X 10-6 mean 1.6 • 10 -5 overall mean 1.3 X 10-6 *R = rhesus monkeys; C = cynomolgus monkeys.
were immediately obtained for pH and blood gas analysis.w By adjusting the volume output from the respirator, arterial pH, carbon dioxide (PaCO~), and oxygen (PaO2) values were kept within the physiological range during surgery. Thereafter, analysis of arterial pH and blood gas was performed during each measurement of CBF. Hematocrit determinations, required for CBF calculation, were carried out four to six times in the course of each experiment. Mean arterial blood pressure (MABP) was continuously monitored by a pressure transducer ]l connected to the femoral artery catheter. Cerebrospinal fluid pressure was also continuously monitored by a similar pressure transducer connected to a catheter positioned in the lumbar subarachnoid space. A cranial twist-drill hole (1.5 mm diameter) was made 0.5 to 1.0 cm dorsal to the nasion in the animals to be subjected to subarachnoid injections. Hemostasis was achieved with bone wax, and the defect was sealed until the time of subarachnoid injection. Cervical dissection to the common carotid artery bifurcation was performed with the aid of an operating microscope. A 7.0 silk purse-string suture was then placed in the wall of the common carotid Cerebrovaseular response to blood and serotonin artery approximately 2 cm proximal to the bifurcation; the diameter of the circle formed by the pursestring suture was approximately 1 ram. A No. 20 catheter was inserted into the common carotid artery through the space enclosed by the suture and threaded to the origin of the internal carotid artery (ICA). The external carotid artery was clipped at its origin using a modified aneurysm clip. The carotid artery catheter was then connected to an injector device via a No. 16 catheter and three-way stopcock assembly. At the end of the experiment the carotid catheter was removed, and the purse-string suture tightened to close the small arteriotomy.
Before subarachnoid injection, a circumferentially bevelled, No. 19 spinal needle was inserted (under fluoroscopy) along the floor of the anterior fossa into the chiasmatic cistern. Adequate placement of the needle was confirmed with return of CSF. The needle was then secured to the skull by a screw device.
Three ml of fresh autogenous arterial blood, artificial CSF, 6 or serotonin solution was injected into the subarachnoid space within approximately 25 seconds. In all experiments, artificial CSF was freshly prepared from stock solutions just before SAH. The serotonin solution was prepared by mixing a small volume (0.5 or 5 ml) of serotonin stock solution (1 X 10 -3 M) into 100 ml of artificial CSF to produce a final serotonin concentration of 5 X 10 ~ M or 5 X 10 5 M. All solutions were adjusted to pH 7.35 and to a temperature of 36 ~ to 38 ~ C before subarachnoid injection.
Experimental Design
The experimental design for the in vivo experiments consisted of three major experimental categories that were established on the basis of the type of subarachnoid injection to be performed; blood, serotonin, and artificial CSF. Each major category was then subdivided into one group that would receive cyproheptadine and one group that would not receive it:
Group 1: SAH Group 2: SAH followed by serotonin blocking agent (intravenous cyproheptadine, 1.0 mg/kg) Group 3: Subarachnoid serotonin injection Group 4: Subarachnoid serotonin injection followed by serotonin blocking agent Group 5: Subarachnoid artificial CSF injection (mock SAH) Group 6: Mock SAH followed by serotonin blocking agent (intravenous cyproheptadine, 1.0 mg/kg).
These treatment categories were assigned to randomized blocks; each randomized block containing the six treatment categories in random order. Experiments were then performed according to this design. A total of 30 monkeys were utilized in this series of experiments, each treatment group containing five animals.
The major variables measured were rCBF, cerebral vessel caliber, and cerebral perfusion pressure (MABP-CSF pressure). Secondary variables measured included PaCO~, PaO~, pH, heart rate, and hematocrit. All statistical comparisons of pre-and post-subarachnoid injection values were done using the Student's t-test.
After completion of the above experiments, a tenfold increase of the serotonin concentration was injected into the subarachnoid space of an additional four monkeys. The experimental protocol was slightly different for these animals in that cerebral angiograpby was also performed immediately following subarachnoid injection and only two to three rCBF measurements were made before taking the final angiograms. These animals did not receive cyproheptadine.
Regional CBF and Vessel Caliber Measurements
Cerebral blood flow was measured from four cerebral regions and the orbitomaxillary and cerebellar regions as previously described. 11 However, in the present study, an automatic injector system was used to inject lS3Xe into the ICA? 4 Cerebral arterial caliber measurements were obtained from lateral angiograms as previously described. Changes in CBF, u whether spontaneous or induced by subarachnoid injection, invariably occurred simultaneously and almost equally in all four cerebral regions monitored. Therefore, CBF values used for analysis represent the mean of the four cerebral regions. In all cases, the CBF values were determined using the height/area method of analysis.
The intradural ICA was the most consistently well visualized on lateral angiograms. Therefore, caliber measurements from this site were used for most of the data analysis.
Results
Experiments In Vitro
Values for the serotonin bioassay determinations are given in Table 1 . The mean serotonin concentration value (1.6 X 10 5 M) for cynomolgus monkey serum was higher than the mean value for rhesus monkey serum. This discrepancy, however, was due to a very high value obtained from one cynomolgus monkey (Monkey C-l). The mean concentration value obtained for cynomolgus monkey serum is 7. Peak CSF pressures observed during subarachnoid injection of 3 cc of blood, serotonin solution, or artificial CSF were 126 + 36 mm Hg (n = 7), 121 4-33 mm Hg (n= 10), and 129 4-52 mm Hg (n=7), respectively. These increases in CSF pressure were often accompanied by increased MABP, bradycardia, and EKG changes. Premature ventricular contractions, S-T elevations, T-wave inversions, and arrhythmias were frequently noted. The EKG pattern and MABP usually returned to normal in 3 to 5 minutes. The CSF pressure remained elevated after SAH but returned to normal levels following subarachnoid serotonin injection and mock SAH.
Mock Subarachnoid Hemorrhage. The effects of mock SAH on CBF (mean hemispheric blood flow), cerebral vessel caliber (intradural ICA), and cerebral perfusion pressure (CPP) are shown in Fig. 2 . Cerebral perfusion remained at or near pre-SAH levels during the 2-to 21/2-hour period after mock SAH. Cyproheptadine administration in five of the 10 animals at approximately 1 hour after mock SAH had no effect on CBF. Similarly, cerebral vessel caliber (intradural ICA) was unchanged after mock SAH in 10 animals or following subsequent cyproheptadine administration in five of these animals. The CPP remained constant except for a 10% to 15% decrease during the latter part of the experiments in the group of five animals without cyproheptadine.
Subarachnoid Hemorrhage. The effects of SAH on CBF (mean hemisphere blood flow), cerebral vessel caliber (intradural ICA), and CPP are shown in Fig.  3 . After SAH, a significant but transient decrease in CBF occurred; within 1 hour, CBF had returned to pre-hemorrhage levels and subsequently remained unchanged whether or not cyproheptadine was administered.
The intradural ICA caliber was significantly decreased in 1 hour after SAH, and at 21/2 to 3 hours in the animals not receiving cyproheptadine. Caliber of the intradural ICA in animals receiving cyproheptadine was not significantly different from the pre-SAH value; however, the recovery of intradural ICA caliber observed following cyproheptadine was minimal. Although all animals demonstrated some post-SAH decrease in intradural ICA caliber, only three had decreases in excess of 25%.
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The CPP, like the CBF, was significantly decreased immediately after SAH, suggesting that the transient decrease in CBF observed following SAH may have been partly due to a fall in CPP.
Subarachnoid Serotonin Injection. The effects of subarachnoid serotonin injection (mean hemispheric blood flow), cerebral vessel caliber (intradural ICA), and CPP are shown in Fig. 4 . Subarachnoid injection of serotonin at 5 X 10 -6 M concentration caused a small nonsignificant decrease in CBF in this group of 10 animals. Intradural ICA caliber and CPP remained unchanged after subarachnoid serotonin injection and following subsequent cyproheptadine administration in five of the animals.
A further series of experiments was then carried out in four monkeys. The concentration of the serotonin solution injected into the subarachnoid space in these animals was 5 x 10 ~ M. The effects of this injection on CBF (mean hemispheric blood flow), cerebral vessel caliber of the middle cerebral artery (MCA), and CPP are shown in Fig. 5 . The CBF decreased following subarachnoid serotonin injection, and was significantly lower than pre-SAH levels at 40 minutes after the injection. A subsequent gradual recovery of CBF occurred which was complete in 11/2 hours.
The results of vessel caliber measurements are shown for the MCA, which exhibited the greatest degree of spasm following subarachnoid serotonin injection. Cerebral angiography performed at 4 to 5 minutes following serotonin injection revealed that the spasm occurred almost immediately. However, relaxation of this spasm occurred over the next few hours, and at 2 to 21/2 hours vessel caliber was not significantly different from the pre-SAH value.
Discussion
Studies In Vitro
Bioassay determination showed that, after clotting, the serotonin concentration of monkey serum is approximately 5 X 10 -8 M. This value is similar to the serum serotonin concentration obtained in man/ baboons, 17 and dogs# Application of serotonin at 5 X 10 -6 M to isolated monkey cerebral vessels produced near-maximal contractions in all cases and these contractions were completely blocked by a cyproheptadine concentration of 5 X 10 6 M. This concentration of cyproheptadine was also highly effective in blocking serum-induced contractions in the same cerebral vessels. Thus, it appeared that the vasoconstrictive activity of the serum was due to serotonin. Other vasoconstrictive agents that might have been present include norepinephrine and prostaglandins, in particular PGF2~. However, marked contractions of monkey cerebral vessels were produced by PGF2~ in the presence of cyproheptadine. Gilbert and Goldberg 8 have demonstrated that cyproheptadine (10 8 M) does not alter norepinephrine response in isolated canine carotid and femoral arteries.
These results suggested that the cerebral vasospasm -/ due to blood in the subarachnoid space could be due to "i the cerebral vasoconstrictor effect of serotonin and ~ 7o that this vasoconstriction could be aborted by cyproheptadine.
so
Studies In Vivo Subarachnoid injection of artificial CSF had no effect on cerebral vessel caliber or CBF. Subarachnoid hemorrhage, induced by injection of blood into the prechiasmatic cistern, resulted in a significant but transient decrease in CBF in all regions of the brain; a pattern that has been observed by other investigators under similar experimental conditions? ,~2 Following an initial decrease, CBF returned to normal levels within 1 hour, in spite of a significant persistent decrease in cerebral vessel caliber. These results are in accord with the findings of other investigations, ~1,~9 in which CBF was found to correlate poorly with the presence of cerebral vasospasm. Intravenous administration of cyproheptadine failed to relieve the cerebral vasoconstriction induced by SAH. Two possible explanations for this finding are: 1) the vasoconstriction was caused by some agent other than serotonin, or 2) cyproheptadine, when administered intravascularly, does not reach the cerebral arterial smooth muscle in sufficient concentrations to have. any effect.
An unexpected finding in these experiments was the lack of effect on rCBF or cerebral vessel caliber of subarachnoid injections of serotonin at 5 X 10 6 M concentration. This concentration of serotonin produced near-maximal contractions of monkey cerebral arteries in vitro. Although some dilution of the serotonin may have occurred upon injection into the CSF spaces, the volume injected was sufficient to displace essentially all of the CSF in the basal cisterns. These results suggest that cerebral vessels in vivo do not display the same sensitivity to serotonin as isolated cerebral vessels. Allen, et al.? 4 have performed a comprehensive study of the role of serotonin in the genesis of cerebral vasospasm. In their initial in vitro study, 3 in which segments of dog MCA on basilar arteries were used, serotonin was the only agent tested that produced a maximal contraction at concentrations (5 x 10 7 M) known to be present in blood~ In the present in vitro study, the concentration required for maximal contraction of monkey cerebral arteries was 10 to 15 times greater. Toda and Fujita 1~ obtained maximal contractions of dog cerebral arteries with 1 X 10 e M serotonin; in the same study, human cerebral arteries obtained at autopsy were maximally contracted when serotonin concentration reached 5 X 10 -~ M. Allen, et al.,~ also tested human cerebral arteries and found that the maximal contraction was 5 X 10 -7 M. Moreover, serotonin concentrations of CSF obtained from two patients 4 to 17 days after SAH were 1 to 2 X 10 -7 M, while CSF from control patients without SAH had no 
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and standard deviation of mean hemispheric blood flow (CBF), middle cerebral artery (MCA) caliber (VC), and cerebral perfusion pressure (CPP) for four animals subjected to subarachnoid injection of a 5 x 10 ~ M serotonin solution (3 ml) (SSI).
in vitro contractile activity. This evidence indicates a major role for serotonin in the production of cerebral vasospasm.
However, the results obtained by Allen, et al., 14 are difficult to reconcile with the observations of the present study; subarachnoid injections of serotonin 100 times greater than those observed by Allen, et al., 2 in the CSF of SAH patients with vasospasm produced only transient decreases in CBF and vessel caliber in the monkey. The duration of these changes was ll/: to 2 hours, and the magnitude of the decreases, while significant, was not large. Allen, et al., 4 found that maximal contractions of canine cerebral arteries were obtained with 5 x 10 -7 M serotonin. However, in a subsequent study, 1 cisternal injections of serotonin in dogs at much higher concentrations (1 X 10 6 to 1 x 10 -s M) produced only 20% to 30% decreases in the diameter of the basilar artery. These results, and the similar results obtained in the present study in monkeys, indicate that the use of in vitro preparations of cerebral arteries produces large overestimations of the ability of serotonin to constrict cerebral arteries in the intact animal. Furthermore, it appears that large non-physiological concentrations of serotonin are required to produce significant in vivo cerebral vasospasm. Martins, et al., 1~ found that a maximal in vitro contraction was obtained with a serotonin concentration of 6 x 10 -e M. In contrast, irrigation of the brain surface with X 10 -8 M serotonin produced only a 10% narrowing of pial arterioles.
These results suggest a lack of in vivo sensitivity of cerebral arteries to serotonin. It should be emphasized, however, that in this and previous studies the effect of serotonin has been tested on normal cerebral arteries. Fraser, et al., 7 have reported that there is a marked decrease in catecholamine fluorescence in the perivascular nerves of cerebral arteries following experimental SAH. Duckies, et al., 5 and Svendgaard, et al., ~5 have recently shown that cerebral arteries revealed an increase in sensitivity to norepinephrine and serotonin following SAH. Thus, cerebral arteries appear to display post-denervation supersensitivity following introduction of blood into the subarachnoid space. The severity of the vasospasm observed in post-SAH patients may, therefore, be determined by two factors: 1) the concentration of vasoconstrictor agents such as serotonin and norepinephrine, and 2) cerebral arterial sensitivity to these agents. It is evident that further attempts to investigate cerebral vasospasm must take both of these factors into consideration.
